Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases
- PMID: 6831397
Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases
Abstract
In many animal models, primary tumor removal produces increased proliferation of cells in metastatic foci. The present investigations using a murine mammary tumor were carried out to determine how a variation in the time interval between primary tumor removal and administration of a single dose of cyclophosphamide (CY) affected labeling indices of residual tumor cells, their growth, and animal survival. The CY (240 mg/kg) had a more favorable effect when given on the day of tumor removal than 3 days after, a time when the labeling index (LI) of metastases was at a peak. It was least effective if given at 7 days following primary tumor excision, when the LI had returned to the preoperative level. The greatest effect occurred when the CY was given prior to operation. It completely prevented the increase in LI resulting from tumor removal, more effectively suppressed the growth of residual tumor, and prolonged survival to a greater extent than was noted under any other circumstance. The interval between tumor removal and administration of a relatively small amount of CY (60 mg/kg) was critical. When given on the day of tumor removal, an increase in LI of the residual focus occurred which was greater than that occurring as a result of tumor removal. When given 3 days after tumor removal, the smaller dose was almost as effective in suppressing LI as was the larger. From a kinetic standpoint, there was no advantage in reducing the tumor burden prior to the use of chemotherapy. The tumor response in this model suggests that, for the most effective control of metastases, the largest tolerable dose of chemotherapy would best be used at the time of or before primary tumor removal. The results provide a biological rationale for the use of perioperative adjuvant chemotherapy.
Similar articles
-
Interrelation between tumor cell proliferation and 17-fluoresceinated estrone binding following primary tumor removal, radiation, cyclophosphamide, or tamoxifen.Cancer Res. 1983 Nov;43(11):5244-7. Cancer Res. 1983. PMID: 6616461
-
Modeling growth kinetics and statistical distribution of oligometastases.Semin Radiat Oncol. 2006 Apr;16(2):111-9. doi: 10.1016/j.semradonc.2005.12.006. Semin Radiat Oncol. 2006. PMID: 16564446 Review.
-
Effect of surgical removal on the growth and kinetics of residual tumor.Cancer Res. 1979 Oct;39(10):3861-5. Cancer Res. 1979. PMID: 476622
-
Effect of cyclophosphamide on survival of mice and incidence of metastatic tumor following intravenous and intracardial inoculation of tumor cells.Cancer Res. 1984 Sep;44(9):3902-6. Cancer Res. 1984. PMID: 6744306
-
Concepts for treatment of micrometastases developed in murine systems.AJR Am J Roentgenol. 1976 Mar;126(3):500-11. doi: 10.2214/ajr.126.3.500. AJR Am J Roentgenol. 1976. PMID: 178196 Review.
Cited by
-
Danggui Buxue Decoction in the Treatment of Metastatic Colon Cancer: Network Pharmacology Analysis and Experimental Validation.Drug Des Devel Ther. 2021 Feb 24;15:705-720. doi: 10.2147/DDDT.S293046. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 33658761 Free PMC article.
-
Surgery for primary tumor benefits survival for breast cancer patients with bone metastases: a large cohort retrospective study.BMC Cancer. 2021 Mar 4;21(1):222. doi: 10.1186/s12885-021-07964-9. BMC Cancer. 2021. PMID: 33663462 Free PMC article.
-
Some aspects of size-dependent differential drug response in primary and metastatic tumors.Cancer Metastasis Rev. 1985;4(1):27-39. doi: 10.1007/BF00047735. Cancer Metastasis Rev. 1985. PMID: 3888381 Review.
-
Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.Ann Surg. 2002 Sep;236(3):295-302; discussion 302-3. doi: 10.1097/01.SLA.0000027526.67560.64. Ann Surg. 2002. PMID: 12192316 Free PMC article.
-
Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.Cancer Manag Res. 2021 Jul 6;13:5413-5422. doi: 10.2147/CMAR.S313013. eCollection 2021. Cancer Manag Res. 2021. PMID: 34262349 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical